Japan's BioComo Pursues Novel Ligand Approach To Immuno-Oncology
Avoids 4-1BB/OX-40 Toxicity Issues
Executive Summary
Japan bioventure BioComo was set up around 10 years ago and has since been honing its technology platform. It is now preparing to move into the clinic with a novel vector for immuno-oncology and to raise new funds to support pipeline development.
You may also be interested in...
Japan's Cost Effectiveness Assessment Needs Change: EFPIA
European industry federation says first practical application of Japan’s cost effectiveness assessment system has highlighted a number of problems for both the scheme and its members, and calls for changes.
Takeda Escapes COVID Impact With 2% Underlying Growth
Takeda continued to prove largely resistant to the business impact of the pandemic last fiscal year, when it made solid progress and exceeded a number of post-Shire targets. R&D spending is set to ramp-up as the Japanese firm progresses its 'Wave 1' pipeline to market.
New Asia Expansion For BioNTech As It Builds On Global Success
German mRNA specialist choses Singapore as its first regional hub in Asia Pacific, where it also plans to build a manufacturing site to support the global supply of both vaccines and therapeutics and a regional “rapid response” capability for future pandemics.